Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium continues to show a significant effect on disability worsening in people with progressive forms of multiple sclerosis (MS), even in those without signs […]
The post ECTRIMS 2025: Vidofludimus calcium shows promise against MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com